Oppenheimer would be buyers of Veru ahead of January’s top line readout
The Fly

Oppenheimer would be buyers of Veru ahead of January’s top line readout

Oppenheimer notes that Veru (VERU) presented a meta-analysis of results from four prior placebo-controlled Phase 2 and 3 clinical studies of enobosarm at the ObesityWeek meeting. The firm, which remains positive on the opportunity for enobosarm to pair with GLP-1-based therapy to yield higher-quality and more weight loss, would be buyers ahead of January’s top line readout from the Phase 2b QUALITY trial, says the analyst, who keeps an Outperform rating and $5 price target on Veru shares.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App